Genmab

	16/6 15:42 af Helge Larsen/PI-redaktør	Transactions in Connection with Share Buy-back Program (link)
	16/6 14:58 af wisuwa	Nå... Har været lidt fraværende i Genmab-regi. Hvad ser vi ind i nu? Hvad er kurstriggerne? Og nogle der har regnet på et EOY kursniveau? :)
	16/6 12:31 af Raun	Ja enig - det er jo vildt imponerende :-)
	16/6 11:56 af gentogen	"Lovende" er da vist en underdrivelse...
	16/6 07:29 af ProInvestorNEWS	Genmab har lovende resultater med kræftmiddel i lymfekræftform (link)
	15/6 20:03 af E L	Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL (link)
	15/6 15:38 af E L	sry that's the same one lol
	15/6 15:37 af E L	Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease (link)
	15/6 15:14 af Solsen	(link) Flotte resultater på Genmab bispecific vi ser i NHL og MM. Specielt imponerede med epco i first line kombo.
	15/6 14:59 af Solsen	:-)
	15/6 14:34 af Helge Larsen/PI-redaktør	Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT) (link)
	15/6 14:34 af E L	"These promising results compare favorably to other regimens in 1L and may provide higher cure rates for patients with 1L DLBCL than SOC", suggesting that further exploration is warranted.
	15/6 14:33 af E L	Lymphoma Hub @lymphomahub CONGRESS \| #EHA2025 \| PRESENTATION Daniel Kerr, @TGHCares presents updated results from the epcoritamab + pola-R-CHP cohort of the phase Ib/II EPCORE NHL-5 trial (N = 37). (link)
	15/6 14:30 af Bulder	Epco fortsætter sin sejrsgang. Det bliver stort - ad åre.
	15/6 11:37 af JKY_VH	Super og mange tak for den Budweis:-)
	15/6 11:11 af Budweis	Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
	15/6 11:11 af Budweis	Ser lovende ud (link)
	14/6 13:52 af Helge Larsen/PI-redaktør	(Artiklen om Genmab kræver ikke abonnement)
	14/6 13:51 af Helge Larsen/PI-redaktør	Oversigt: Ny udgave af ØU Life Science – Genmab accelererer mod blockbusterstatus med Rina-S efter data (link)
	13/6 09:05 af gentogen	Thanks EL for the link 15:24 yesterday. Pure KYSO...
	12/6 15:24 af E L	Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma (link) EHA 2025
	12/6 15:23 af E L	they may have, but for a relatively small value. If I remember correct, they invested $20mn and sold a part of that for +-$60mn (?) . The remainder collapsed in value...
	12/6 13:04 af Solsen	I belive Genmab still have some shares left i CureVac.
	12/6 12:50 af E L	BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer (link)

	10/6 17:00 af lahn1	Yes as 4-1BB has a history of poor tolerability, it seems logical to be able to show durable tolerability with zero or low discontinuation rates. Docetaxel having 15-20% discontinuation as SOC in 2L NSCLC.
	10/6 16:55 af E L	only Time to Treatment Discontinuation Due to AE is new. (the other was already there, the old 5. ) to me the question is more; why wasn't that there in the first place (logical measure)
	10/6 16:54 af lahn1	Sorry, jeg fik vist blandet koncentratione af acasunlimab i plasma sammen med t-cell exhaustion.
	10/6 16:45 af Solsen	Acasunlimab has a huge potential. Tahi seems very bullish. But data on limited pts until now. But if they can show high number and long responses in NSCLC in second line it could be big.
	10/6 16:44 af lahn1	De 2 nye endpoint kan vel være andet end positive, selvom jeg primært ser dem som det. Lyder plasma kontrol lidt som vi var inden på ved resultaterne af ph2, at en individuel doserings regime (timing) ift Aca koncentrationen i plasma ser ud til at kunne optimere effekten ? Discontinuation rate er vel kun forberedelse på godkendelse vs Docetaxel i 2 L og måske bedre forståelse for AE ift med mulige fremtidige kombinationer. Hvordan læse I andre de nye end points ?
	10/6 16:40 af Solsen	Yes I agree.
	10/6 16:22 af E L	the fact that they started a Melanoma trial with Acasunlimab is a strong signal i would think
	10/6 16:15 af Solsen	I have been a little cautious on Acasunlimab after Biontech left. But there is a chance that Biontech where wrong.
	10/6 16:11 af Solsen	Looks like Rina-S also are running fast :-)
	10/6 16:01 af E L	ASCO 2025 presentations via (link)
	10/6 16:00 af E L	In full swing... let's see if they can replicate the speed with which they executed on Epcoritamab... that went very fast (is going very fast i should say), but this they have to do alone...
	10/6 15:38 af Solsen	Plus 100 new sites :-) And boost targets. Are we back on trac ?
	10/6 15:21 af w	(link)
	10/6 15:21 af w	AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength. Hæver fra 2566 til 2661kr
	10/6 15:10 af E L	the Ph3 Acasunlimab trial adding a lot of new recruitment centers (link)
	10/6 13:22 af Solsen	Det bliver spændende at følge @Raun
	10/6 11:56 af Raun	Biontech BNT116 - (link)
	10/6 10:04 af E L	Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma (link)
	10/6 06:47 af ProInvestorNEWS	Knock-Your-Socks-Off-News – June 2025 (link)
	8/6 20:19 af Solsen	..Lundbeck. Ved ikke om jeg rigtigt tror på stoffet ;-)
	8/6 20:18 af Solsen	Lidt om samarbejdet med Lundbec (link)
	6/6 20:01 af gentogen	Fra samme kilde.......(link)
	6/6 14:19 af bikube	Det er da positivt, at han vil sætte tempoet op, men hvis det går ud over sikkerheden i deres arbejde, er det jo ikke entydigt godt. Man kan vel så påregne, at der skal køres fase 4 på nogle godkendte stoffer.
	6/6 13:03 af Legolas23	FDA vil fremskynde godkendelsen af lægemidler til sjældne sygdomme (link)
	6/6 13:01 af ProInvestorNEWS	Europa/aktier: Sundhedsaktier vinder frem mens investorer kigger mod toldforhandlinger (link)
	6/6 11:54 af Solsen	Nej der er sikkert ikke noget i det.